← Research library

Mexidol in chronic cerebral ischemia: the MEMO placebo-controlled trial

Randomized study in people · 2021

What was studied
318 randomized, 159 per group at 15 Russian and Uzbek centers. The paper’s end-of-treatment MoCA analysis included 157 and 155.
Main finding
The 318-person MEMO trial reported a 2.05-point MoCA advantage at treatment end for chronic cerebral ischemia (95% CI 1.51–2.58). Adverse events affected 15/159 with Mexidol and 21/159 with placebo.

MoCA change · +4.22 vs +2.17 points · Mexidol vs placebo, 157 vs 155 in Table 3. · Between-group difference 2.05 (95% CI 1.51–2.58), p<0.000001

Reported findings and study design

Multicenter double-blind randomized trial. The primary endpoint was change in Montreal Cognitive Assessment score from screening to the final visit.

Population or model 318 randomized, 159 per group at 15 Russian and Uzbek centers. The paper’s end-of-treatment MoCA analysis included 157 and 155.

Dose, route and schedule

500 mg Mexidol intravenously once daily for 14 days, followed by 250 mg Mexidol Forte orally three times daily for 60 days. The control group received matching placebo on the same schedule.

Protocol source ↗ · Original journal methods and Tables 3 and 9, with ClinicalTrials.gov results reviewed.

Results · Original journal methods and Tables 3 and 9, with ClinicalTrials.gov results reviewed.
MeasureResultComparison, timing and statistics
MoCA change+4.22 vs +2.17 pointsMexidol vs placebo, 157 vs 155 in Table 3. · Between-group difference 2.05 (95% CI 1.51–2.58), p<0.000001
Digit symbol substitution+8.00 vs +5.00 pointsMedian change by last visit.
Fatigue scale (MFI-20)−8.33 vs −4.80 pointsp=0.010
Participants with adverse events15/159 vs 21/159The paper reports no serious adverse events. · p=0.288

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The 74-day trial measured cognitive scores in chronic cerebral ischemia. Effects on long-term independence and acute stroke recovery remain uncertain.
  • The registry and secondary analyses report the same trial and use different denominators for some analyses.

Related publications may describe some of the same participants or experiments.

Source details

Original journal methods and Tables 3 and 9, with ClinicalTrials.gov results reviewed.

Sources checked

Citation

Randomized trialFull text available

A. I. Fedin, V. V. Zakharov, M. M. Tanashyan, and colleagues. Mexidol in chronic cerebral ischemia: the MEMO placebo-controlled trial Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7–16. NCT06834490.

Study source ↗ · DOI 10.17116/jnevro20211211117 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards